Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer

被引：0
|
作者：
Shigeki Nanjo
Akito Hata
Chiyuki Okuda
Reiko Kaji
Hideaki Okada
Daisuke Tamura
Kei Irie
Hiroshi Okada
Shoji Fukushima
Nobuyuki Katakami
机构：
[1] Institute of Biomedical Research and Innovation Hospital,Division of Integrated Oncology
[2] 2-2,Department of Medical Oncology
[3] Minatojima-minamimachi,Department of Respiratory Medicine
[4] Chuo-ku,Department of Pharmacology
[5] Kobe 650-0047,Department of Pharmaceutics
[6] Japan,undefined
[7] Kobe Minimally Invasive Cancer Center,undefined
[8] Kobe 650-0046,undefined
[9] Japan,undefined
[10] Kobe University Hospital,undefined
[11] Kobe 650-0017,undefined
[12] Japan,undefined
[13] Institute of Biomedical Research and Innovation Hospital,undefined
[14] Kobe 650-0047,undefined
[15] Japan,undefined
[16] Faculty of Pharmaceutical Science,undefined
[17] Kobe Gakuin University,undefined
[18] Kobe 650-8586,undefined
[19] Japan,undefined
来源：
British Journal of Cancer | 2018年 / 118卷
关键词：
osimertinib; leptomeningeal metastases; T790M; cerebrospinal fluid;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：32 / 37
页数：5
相关论文
共 50 条
  • [1] Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
    Nanjo, Shigeki
    Hata, Akito
    Okuda, Chiyuki
    Kaji, Reiko
    Okada, Hideaki
    Tamura, Daisuke
    Irie, Kei
    Okada, Hiroshi
    Fukushima, Shoji
    Katakami, Nobuyuki
    BRITISH JOURNAL OF CANCER, 2018, 118 (01) : 32 - 37
  • [2] Osimertinib at 80mg for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
    Hata, A.
    Nanjo, S.
    Okuda, C.
    Kaji, R.
    Masago, K.
    Fujita, S.
    Irie, K.
    Okada, H.
    Okada, H.
    Okada, H.
    Fukushima, S.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease
    Arulananda, Surein
    Do, Hongdo
    Rivalland, Gareth
    Loh, Zoe
    Musafer, Ashan
    Lau, Eddie
    Mitchell, Paul
    Dobrovic, Alexander
    John, Thomas
    JOURNAL OF THORACIC DISEASE, 2019, 11 (05) : 1756 - 1764
  • [4] Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer
    Yu, Helena A.
    Paz-Ares, Luis G.
    Yang, James Chih-Hsin
    Lee, Ki Hyeong
    Garrido, Pilar
    Park, Keunchil
    Kim, Joo-Hang
    Lee, Dae Ho
    Mao, Huzhang
    Wijayawardana, Sameera R.
    Gao, Ling
    Hozak, Rebecca R.
    Chao, Bo H.
    Planchard, David
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 992 - 1002
  • [5] Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
    Joan Rou-En Choo
    Chee-Seng Tan
    Ross A. Soo
    Targeted Oncology, 2018, 13 : 141 - 156
  • [6] Osimertinib in EGFR T790M-Positive Lung Cancer
    Nishino, Mizuki
    Hatabu, Hiroto
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (20): : 1992 - 1993
  • [7] Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
    Choo, Joan Rou-En
    Tan, Chee-Seng
    Soo, Ross A.
    TARGETED ONCOLOGY, 2018, 13 (02) : 141 - 156
  • [8] Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer
    Lamberti, Giuseppe
    Andrini, Elisa
    Ricciuti, Biagio
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S1831 - S1834
  • [9] The different path of T790M-positive EGFR-mutant lung cancer
    Yoon, Shinkyo
    Choi, Chang Min
    Lee, Jae Cheol
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [10] Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
    Lamb, Yvette N.
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2017, 12 (04) : 555 - 562
12345